CellCentric key facts
as of Oct 2026- Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers.
- CellCentric is valued at approximately $382.5M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $280.5M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($116.5M) in Apr 2025.
- Notable investors include Innovate UK, RA Capital Management, 5Y Capital, Future Planet Capital, Cambridge Enterprise Ventures — 20 tracked in total.
- 4 institutional filers report fund marks on CellCentric across 7 filings.
- Status: Privately Held (backing).
Nothing comparable since the round — shown at its later-stage round, Apr 2025 ($382.5M post-money).
- ·The complete investor list: 20 names
- ·Watch CellCentric: the Monday email on marks, rounds and moves
Institutional fund marks on CellCentric
4 filers · latest Jul 20264 SEC-registered funds reported 7 fair-value marks on CellCentric between May 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
CellCentric funding rounds
2 roundsWho backs CellCentric
20+CellCentric valuation
CellCentric is valued at approximately $382 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Apr 2025, at a $382 million post-money valuation.
Recent activity
In the last 90 days, CellCentric's record added 4 institutional fund marks (latest period Jul 2026).
How much has CellCentric raised?
CellCentric has raised $281 million in total; 2 of its rounds are on record. The largest on record was a $35.5 million Series B in Jul 2024; the most recent was an $116 million Series C in Apr 2025.
Institutional holders and vehicles
4 SEC-registered funds reported 7 fair-value marks on CellCentric between May 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
CellCentric investors
20 investors are on record for CellCentric, including Innovate UK, RA Capital Management, 5Y Capital and Future Planet Capital. By type, the record holds 8 venture capital firms and 1 asset manager. The Series C in Apr 2025 drew 3 investors.
Comparable companies
Comparable biotechnology names by valuation on PrivateMarketView: Profluent ($525 million), Checkerspot ($347 million) and Ansa Biotechnologies ($269 million).
About CellCentric
Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers. The company's novel small-molecule inhibitors inhibit the common bromodomain of twin proteins down-regulate the androgen receptor and also deplete the adaptive AR splice variant forms, thereby enabling clients to treat specific cancers and notably relapsed refractory multiple myeloma.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2003
- Employees
- 46
- Website
- cellcentric.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.